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Purpose: Differences in the reporting methods of results for arteriovenous (AV) access can dramatically affect apparent
outcome. To enable meaningful comparisons in the literature, the Society for Vascular Surgery and the American
Association for Vascular Surgery (SVS/AAVS) recently published reporting standards for dialysis access. The purpose of
the present study was to determine infection rates, patency rates, and possible predictive factors for prosthetic thigh AV
access outcomes with the reporting standards of the SVS/AAVS.
Methods: A retrospective analysis was performed of all patients who underwent placement of thigh AV access by the
Surgical Teaching Service at Greenville Memorial Hospital between 1989 and 2001. Outcomes were determined based on
SVS/AAVS Standards for Reports Dealing with AV Accesses. The rate of revision per year of access patency was also
determined; this end point more accurately reflects the true cost and morbidity associated with AV access than do patency
or infection rates alone.
Results: One hundred twenty-five polytetrafluoroethylene thigh AV accesses were placed in 100 patients. Nine accesses
were excluded from the study, six because there was no patient follow-up and 3 as a result of deaths unrelated to the access
procedure and which occurred less than 30 days after access placement. There were six (4%) late access-related deaths.
There were 18 (15%) early access failures, related to infection in 14 cases (12%), thrombosis in three cases (2%), and steal
in one case (1%). Early failure was more common in patients with diabetes mellitus (P .036). The primary and secondary
functional patency rates were 19% and 54%, respectively, at 2 years. Infection occurred in 48 (41%) accesses. The patency
and infection rates were not influenced by patient age, gender, body mass index, or diabetes mellitus. The median number
of interventions per year of access patency was 1.68, and this outcome was positively correlated with body mass index
(P < .001).
Conclusions: Prosthetic AV access in the thigh is associated with higher morbidity compared with that reported for the
upper extremity, and should be considered only if no upper extremity AV access option is available. Early access failure
and the requirement for an increased number of interventions to reestablish and maintain access patency are more
common in patients with diabetes mellitus and obesity. The number of interventions per year of access patency is a
valuable end point when assessing the outcome of AV access procedures. (J Vasc Surg 2004;39:381-6.)
Surgeons are often tasked to provide dialysis access for
patients with no sites available for access in the upper
extremity, because of venous thrombosis, axillosubclavian
arterial occlusive disease, or ischemic complications. An
alternative procedure for arteriovenous (AV) access after
upper extremity options have been expended is the pros-
thetic thigh AV access.
The literature reporting outcomes for prosthetic thigh
AV access is conflicting. Although some studies report a
high rate of infection and limb amputation associated with
prosthetic thigh AV access, others report favorable results,
with patency and infection rates comparable to those
achieved for prosthetic AV access in the upper extremity.
These conflicting conclusions regarding prosthetic thigh
AV access are the result of differences in the methods of
reporting outcomes, which can dramatically alter the appar-
ent patency rates. In an effort to enable meaningful com-
parisons between studies in the dialysis access literature, the
Society for Vascular Surgery and the American Association
for Vascular Surgery (SVS/AAVS) recently published rec-
ommended standards for reports dealing with AV access.1
We report our experience with prosthetic thigh AV
access using the reporting standards for outcome devel-
oped by the SVS/AAVS to assess the durability, infection
rate, and patient factors that influence outcome. We also
determined the rate of revision per year of access patency,
and factors that influence this rate. This approach for
determining outcome more accurately reflects the true cost
and morbidity associated with AV access than do patency
rates alone.
METHODS
Office, hospital, dialysis clinic, and operative reports
were retrospectively reviewed for all patients who under-
went placement of a prosthetic thigh AV access at the
Surgical Teaching Service at Greenville Memorial Hospital
between August 1989 and December 2001. All grafts were
polytetrafluoroethylene (W. L. Gore Co, Flagstaff, Ariz)
From the Academic Department of Surgery, Greenville Hospital System.
Competition of interest: none.
Presented at the Fifty-first Annual Meeting of the American Association for
Vascular Surgery, Chicago, Ill, Jun 8-11, 2003.
Reprint requests: David L. Cull, MD, Academic Department of Surgery,
Greenville Hospital System, 701 Grove Road, Greenville, SC 29605
(e-mail: tcrump@ghs.org).
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/S0741-5214(03)00720-1
381
and ranged in diameter from 6 to 8 mm. The graft size was
selected at the surgeon’s discretion. All grafts were placed
in a loop configuration. The grafts were sewn end-to-side
to either the superficial femoral artery or the common
femoral artery. The venous anastomosis was end-to-side to
the proximal superficial femoral vein, greater saphenous
vein, or common femoral vein.
Primary and secondary functional graft patency rates
were determined with the reporting standards set by the
Committee of Reporting Standards for AV Accesses of the
SVS/AAVS. In accordance with those standards, the fol-
lowing criteria were used to define access patency and
failure. An access was considered patent if it delivered a flow
rate of 350 to 400 mL/min without access recirculation.
An access that was removed, ligated, abandoned, or could
not deliver an adequate flow rate was considered failed, and
patency was calculated up to the time of permanent cessa-
tion of dialysis with that access. Primary patency was de-
fined as the interval from the time of access placement until
any intervention designed to maintain or reestablish access
function. Assisted primary patency was defined as the inter-
val from the time of access placement until access throm-
bosis, including intervening manipulations designed to
maintain functioning of a patent access. Secondary patency
was defined as the interval from the time of access place-
ment until access abandonment. Survival curves were esti-
mated with the Kaplan-Meier product limit method. The
log-rank test was used to compare survival curves. Cen-
sored end points were death, transfer of care to another
institution, transplantation, loss to follow-up, and access
survival to the end of the study. A patient was considered
lost to follow-up if dialysis records ended and transplanta-
tion or death could not be confirmed. The influence of age,
gender, race, body mass index (BMI), and diabetes mellitus
on patency and infection rates was examined first, with the
Fisher exact test for proportions and the Wilcoxon rank
sum test for medians. BMI was subdivided into four cate-
gories for analysis: underweight (BMI18.5), ideal weight
(BMI 18.5-24.9), overweight (BMI 25-29.9), or obese
(BMI 30). Multiple linear regression and Cox propor-
tional hazards modeling were used to assess the combined
influence of risk factors on the frequency of access interven-
tions and patency, respectively. The relationship of BMI to
the frequency of access interventions was assessed with the
Pearson correlation coefficient and linear regression. To
calculate the number of revisions per year of access patency
the following formula was used: number of surgical or
percutaneous interventions performed on the access to
reestablish or maintain function, divided by the number of
months of access patency, divided by 12.
RESULTS
From August 1989 to December 2001, 145 thigh AV
accesses were performed in 111 patients. Twenty-nine
thigh AV accesses were excluded from the study, because of
inadequate follow-up (n  6), use of bovine heterograft
(n  6), and patient death unrelated to the access proce-
dure less than 30 days after access placement (n  3). The
outcomes of 14 cryopreserved femoral vein thigh AV ac-
cesses were published in a previous report and were also
excluded from the present study.2 The study cohort was
thus comprised of 116 prosthetic thigh AV accesses per-
formed in 91 patients.
Demographic data are shown in Table I. Patients in this
cohort were predominantly female (63%) and African
American (64%); their median age was 58 years. Forty-four
percent of patients had diabetes, and 47% were either
overweight or obese. Mean patient follow-up was 20
months (range, 1-111 months).
The arterial inflow was the common femoral artery in
46 patients and the superficial femoral artery in 35 patients.
Table I. Patient demographic data
n %
Number of patients* 100
Age (y)
Median 58
Range 19–85
Gender
Male 37 37
Female 63 63
Race
White 35 35
Black 64 64
Other 1 1
Diabetes mellitus 44 44
Body mass index
Underweight 15 15
Ideal weight 35 35
Overweight 17 17
Obese 27 27
Unknown 6 6
*Includes patients lost to follow-up (n  6) and patient death unrelated to
the access 30 days after access placement (n  3).
Table II. Ipsilateral limb ischemic complications after
thigh arteriovenous access placement
Patient
Ischemic
complication
Months after
access
placement Access status
1 Foot ulcer 2 Patent
2 Revision, BKA
to AKA
4 Patent
3 AKA 2 Patent
4 Revision, BKA
to AKA
1 Patent
5 BKA 4 Patent
6 AKA 10 Patent
7 Rest pain 1 Ligated
8 Revision, BKA
to AKA
4 Ligated
9 AKA 16 Patent
10 AKA 65 Patent
11 AKA 8 Thrombosed
12 Rest pain 18 Ligated
13 AKA 28 Patent
BKA, Below-knee amputation; AKA, above-knee amputation.
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The venous outflow was the greater saphenous vein in 46
patients, the common femoral vein in 26 patients, and the
superficial femoral vein in 14 patients. The operative report
did not delineate the site of the arterial anastomosis in 35
patients or the venous anastomosis in 30 patients. The site
of the arterial or venous anastomosis did not influence the
primary patency rate (both, P  .2). However, use of the
common femoral artery significantly improved survival time
in comparison with the superficial femoral artery: median
access survival, 30 months vs 11 months, respectively (P 
.03). Venous anastomosis was not significantly related to
secondary patency (P  .50).
Early access failure, defined as access abandonment less
than 30 days after placement, occurred in 18 (15%) pa-
tients, and was caused by infection in 14 patients and
thrombosis in 3 patients. One early failure occurred in a
patient whose access was ligated for treatment of arterial
steal. At bivariate analysis, early access failure was signifi-
cantly more common in patients who had diabetes mellitus
(24%) than in those without diabetes (9%; P .036). Age,
gender, race, and BMI were not significantly associated
with early access failure (all, P  .1).
The primary functional patency rate was 34% at 1 year
and 19% at 2 years. The assisted primary patency rate was
37% at 1 year and 24% at 2 years (Fig 1). The secondary
functional patency rate was 68% at 1 year and 54% at 2 years
(Fig 2). The median access survival time was 28 months
(interquartile [IQ] range 6, 79 months). Age, gender, race,
diabetes mellitus, and BMI did not significantly influence
secondary patency (all, P  .1).
Infection requiring surgical intervention (grade 2 infec-
tion, SVS reporting standards) or resulting in patient death
occurred in 48 (41%) accesses. There were 14 early access
infections. Twelve of the early access infections were treated
with graft removal. Two patients died of sepsis before graft
removal. There were 34 late access infections, which oc-
curred between 1 and 64 months (mean, 19 months) after
graft implantation. Nineteen of the late infections were
localized, and were treated with the technique of segmental
graft resection and bypass described by our group.3 Fifteen
of the late access infections could not be treated with
segmental resection and bypass, and required complete or
partial excision of the graft and abandonment of the access.
The overall infection rate was not influenced by age, gen-
der, race, diabetes mellitus, or BMI; however, early graft
failure, which was most often caused by infection (14 of
18), was more common in patients with diabetes mellitus.
There were six (4%) access-related deaths due to infec-
tion. Four patients died within 30 days of removing an
infected access. Two patients with access infection did not
undergo graft excision, and died of sepsis.
Ipsilateral limb ischemia after thigh AV access place-
ment occurred in 13 (11%) patients. Ten (9%) major limb
amputations ipsilateral to the thigh access were performed
between 1 and 65 months (mean, 14 months) after access
placement. In 1 patient a foot ulcer developed 2 months
after access placement. Two accesses were ligated, 1 month
and 18 months, respectively, after placement for treatment
of ischemic rest pain (Table II).
The median number of interventions per year of access
patency was 1.68 (IQ range 0.5, 3.0). The median number
of interventions per year of access patency was 0 (IQ range
0, 1.7) for patients who were underweight, 1.68 (IQ range
0.6, 3.0) for patients who were at ideal weight or over-
weight, and 2.28 (IQ range 1.1, 3.4) for patients who were
obese. The relationship of BMI to the number of interven-
tions per year of access patency is shown in Fig 3. There was
a positive correlation between BMI and the number of
interventions required to reestablish or maintain access
patency (r  0.40; P  .001).
The median patient survival from the time of the first
thigh AV access placement was 24 months (IQ range 12,
62; Fig 4). Patient age and BMI were significantly associ-
ated with patient survival at multivariate analysis. The me-
dian survival for patients younger than 45 years was 41
months (IQ range 15, 75), for those 46 to 65 years was 24
Fig 1. Kaplan-Meier survival curve for primary (solid line) and
assisted primary (dashed line) functional patency. Bars represent
95% confidence interval.
Fig 2. Kaplan-Meier survival curve for secondary functional pa-
tency. Bars represent 95% confidence interval.
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months (IQ range 11, 62), and for those older than 65
years was 17 months (IQ range 6, 42) (P  .049). The
median survival of patients who were underweight was 15
months (IQ range 12, 23), for those with ideal weight or
overweight was 37 months (IQ range 17, 75), and for those
who were obese was 41 months (IQ range 9, 84; P .029).
The median survival of patients with diabetes mellitus was
19 months (IQ range 9, 46 months), compared with
survival of 38 months (IQ range 21, 45) for patients
without diabetes; this difference did not reach statistical
significance (P  .095).
DISCUSSION
Several recently published studies report the outcome
of prosthetic thigh AV access.4-7 The conclusions of these
studies differ dramatically. Some suggest that thigh AV
access is safe, with excellent long-term patency; others
consider it a procedure of last resort, because of the high
rate of complications, such as infection and arterial steal.
Tashjian et al4 recently reported primary and second-
ary patency rates for prosthetic thigh AV access of 71%
and 83%, respectively, at 1 year. The incidence of infec-
tion in their series was 22%. They concluded that the
incidence of infection and thrombosis is comparable to
that of prosthetic upper extremity AV access.4 Khadra et
al,5 in a series of 74 polytetrafluoroethylene thigh AV
accesses, reported a patency rate of 50% at 1 year and an
infection rate of 16%. Bhandari et al6 reported an 85%
1-year total access survival rate and a 35% infection rate
in their series of 49 thigh accesses. In a previous series
from our institution, Taylor et al7 reported primary
access patency of 52% at 1 year, and 47% at 2 years, for
thigh AV access. Taylor et al7 reported a 38% incidence
of major graft complications, including an 18% incidence
of infection and a 16% incidence of distal limb ischemia.
Differing methods of reporting outcomes is, in large
part, responsible for the disparate conclusions derived
from these studies. For example, Tashjian et al4 excluded
accesses lost to infection from patency curves; whereas
Taylor et al7 defined failure as a loss of access function
regardless of the cause, and included accesses lost to
infection in the calculation of patency. Khadra et al5
reported patency as mean access survival time. Patency
results using mean survival time are disproportionately
affected by a few accesses with prolonged patency. Bhan-
dari et al6 did not define patency in their series, and used
a cumulative survival curve to report patency. The stud-
ies by both Taylor et al7 and Khadra et al5 excluded early
access failures from patency calculations. The effect of
different reporting methods on outcome results for AV
access was demonstrated in a recent study by Hodges et
al.8
To enable meaningful comparisons of outcomes from
the AV access literature, the Committee on Reporting
Standards for AV Access of the SVS/AAVS recently pub-
lished reporting standards for AV access studies. Using
these standards we obtained a secondary functional patency
rate for thigh AV access of 68% at 1 year and 54% at 2 years.
Our patency results would be similar to those achieved by
Tashjian et al,4 had they included accesses lost to infection
rather than considering those accesses separately. Our pa-
tency results cannot be compared with the results of Khadra
et al,5 Bhandari et al,6 or Taylor et al,7 because of differ-
ences in reporting methods. However, the median patency
of 24 months reported by Taylor and colleagues is similar to
the 28 months obtained in the current study.
The infection rate for thigh AV access in our series
was 41%. This rate included only those infections that
resulted in the patient’s death or required access revi-
sions or graft excision (grade 2 infections) for treatment.
We did not include those infections treated with antibi-
otic agents alone (grade 1 infections) in the calculation
of the infection rate, because confirmation of minor
infections is unreliable in a retrospective study. The
infection rate in our series is similar to the infection rate
of 35% reported by Bhandari et al,6 but is higher than the
Fig 4. Kaplan-Meier survival curve for patient survival after access
placement. Bars represent 95% confidence interval. *Excludes six
patients with no follow-up.
Fig 3. Scatterplot of body mass index and median number of
interventions required per year of access patency. Line represents
linear regression. Pearson correlation coefficient, 0.40; P  .001.
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16% to 22% reported by other authors. These differences
may be due to differences in patient population, com-
pleteness and duration of patient follow-up, and period
of patient accrual. Both the study by Bhandari et al6 and
the present study included patients with accesses placed
over 12 years, a period that is substantially longer than
the other studies.
The reporting standards for AV access developed by the
SVS/AAVS uses primary, assisted primary, and secondary
patency as measures of success. The cost and morbidity
associated with hemoaccess, however, is also significantly
influenced by the number of interventions required to
reestablish and maintain access patency. Consequently, we
believe that the number of interventions per year of access
patency should be included as an end point for AV access
outcome. We show that the median number of interven-
tions per year of access patency for thigh grafts is 1.68 and
is significantly influenced by BMI.
A review of local complications such as prolonged
puncture site bleeding, pseudoaneurysm, or seroma or
lymphocele, and remote complications such as venous hy-
pertension, neuropathy, and congestive heart failure was
not included in our study unless these complications di-
rectly affected access function. Although these complica-
tions can result in considerable morbidity, the documenta-
tion and grading of severity of these complications is
incomplete and subjective, and cannot be accurately ac-
complished in a retrospective study.
The reported incidence of ischemic limb complications
related to thigh AV access ranges from 1% to 16%.4-7 Ipsilat-
eral ischemic limb complications after thigh AV access place-
ment occurred in 11% of patients in our series, which is higher
than the 4.6% to 8% incidence of limb ischemia reported for
upper extremity AV access.9,10 Several of the ischemic com-
plications in our series, however, occurred many months after
access placement or after the access had thrombosed. In these
cases it could not be determined from the medical record
whether limb loss was related to the AV access or to progres-
sion of arterial occlusive disease.
The literature reports a 47% to 70% secondary patency
rate at 2 years and a 2% to 16% infection rate for prosthetic
AV accesses of the upper extremity.9,11,12 Results of our
study indicate that the secondary patency rate for prosthetic
AV accesses of the thigh is equivalent to that for the upper
extremity, but the infection rate is higher. Therefore place-
ment of prosthetic AV access in the thigh should be con-
sidered if no alternative in the upper extremity is possible.
The thigh AV access can provide prolonged, reliable
dialysis access for patients who have few alternative sites for
access placement. However, patient survival for those who
require a thigh graft is limited, and the morbidity and
mortality associated with the procedure and its complica-
tions are significant. Patients with diabetes mellitus are at
increased risk for early access failure, most often caused by
infection, and there is a direct correlation between BMI and
the number of interventions required to reestablish and
maintain access patency. It may be appropriate for patients
with these risk factors, in whom life expectancy is limited,
that an alternative means of dialysis, such as a tunneled cuff
dialysis catheter, be considered.
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DISCUSSION
Dr Sachinder S. Hans (Warren, Mich). I have one question.
What about size of the graft? Did you use any 4 by 6, or were they
all 6-mm grafts?
Dr David L. Cull. Nine of the accesses were constructed with
8-mm grafts. Six-millimeter grafts were used for the remaining
accesses in this series.
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Dr Hans. And do you have any data on pre-op arterial
status; do you have any segmental pressures or ankle-brachial
indices prior to placing the grafts and then for the progression
down the road?
Dr Cull. This was a retrospective study that covered a 12-year
period. Although the medical record for many of these patients
indicated that they had peripheral arterial disease, there was often
little objective data, such as an ankle-brachial index, to establish the
diagnosis.
Dr Harry Schanzer (New York, NY). I agree with the pre-
senters that this is an access that produces a significant number of
steal syndromes. In my experience, about 10% of them, at least, will
develop, in 2 to 3 years, steal. I have done in the past 4 years three
DRIL procedures in order to save these limbs and save the access.
What have you done in this setting for your patients?
Dr Cull. We have performed DRIL procedures in the upper
extremity. In this particular series of patients the DRIL procedure
was not performed.
Although we had 13 ischemic complications, from this retro-
spective review it is extremely difficult to determine whether this
was due to progression of arterial occlusive disease or related to the
steal. So we really can’t comment on the specific incidence of steal.
Like you, I believe it is significant.
Dr G. Patrick Clagett (Dallas, Tex). I have a question. I’m
very curious to know how you get so many of these patients. We
have a huge access population between our VA Hospital and
Parkland Hospital, and this is an extraordinarily rare access.
Dr Cull. Greenville has a drawing area of about 350,000
people. Essentially all of the vascular access is done by our group.
Consequently, we have 12 dialysis units in our region, and we’re
responsible for taking care of all of those.
Dr Clagett. Do you not do basilic vein transposition, neck-
lace-type accesses, axillary-axillary type of bypasses, things like
those that are alternatives?
Dr Cull. We do basilic vein transpositions and forearm vein
transpositions. We have a series of 20 chest wall AV accesses. We
prefer the thigh AV access to the chest wall access. Although the
complication rate was slightly less for the chest wall access, the
management of those complications associated with the chest wall
access is extremely difficult.
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